Please login to the form below

Not currently logged in
Email:
Password:
I have forgotten my password

Qsymia

This page shows the latest Qsymia news and features for those working in and with pharma, biotech and healthcare.

Novo Nordisk taps Noom for digital help with its push into obesity

Novo Nordisk taps Noom for digital help with its push into obesity

developers. There is a handful of approved drug therapies – including GlaxoSmithKline’s/Roche’s lipase inhibitor, Xenical (orlistat), Eisai’s Belviq (lorcaserin) and Vivus Qsymia (phentermine/topiramate) – but none have been

Latest news

  • Takeda files block on generic diet pill launch Takeda files block on generic diet pill launch

    But despite being third to market among the new generation of obesity therapies after Eisai and Arena's  Belviq (lorcaserin) and Vivus' Qsymia (phentermine/topiramate), both approved 18 months ago, Orexigen ... Actavis and Teva have both already filed

  • FDA panel backs Sprout Pharma's 'female Viagra' FDA panel backs Sprout Pharma's 'female Viagra'

    REMS are already in place for other 'lifestyle' drugs such as Vivus' Qsymia (phentermine/topiramate) for obesity and Pfizer's smoking cessation therapy Chantix (varenicline).

  • Saxenda debuts in US with $1,000-a-month price tag Saxenda debuts in US with $1,000-a-month price tag

    s Contrave (bupropion/naltrexone), Arena/Eisai's Belviq (lorcaserin) and Vivus' Qsymia (phentermine/topiramate), although for patients the monthly cost will fall depending on their insurance cover. ... Contrave costs around $200 per month but for

  • Eisai to make 200 cuts to US operations Eisai to make 200 cuts to US operations

    However, it has quickly faced new competition as two other obesity drugs - Takeda's Contrave and  Vivus' Qsymia - came to the market not long award Belviq.

  • Positive data in Saxenda diabetes prevention study Positive data in Saxenda diabetes prevention study

    the US of three other drugs; Eisai and Arena's Belviq (lorcaserin), Vivus' Qsymia (phentermine/topiramate) and Orexigen's Contrave (naltrexone and bupropion). ... Qsymia turned down by the European Medicines Agency (EMA) on safety concerns.

More from news
Approximately 2 fully matching, plus 24 partially matching documents found.

Latest appointments

  • Anthony Zook resigns as Vivus CEO Anthony Zook resigns as Vivus CEO

    shareholders became unhappy with the way Vivus handled the launch of its obesity drug Qsymia (phentermine/ topiramat). ... This coup was led by investment group First Manhattan Co, which had attempted to replace the entire board of Vivus after Qsymia

More from appointments
Approximately 1 fully matching, plus 0 partially matching documents found.

Subscribe to our email news alerts

PMHub

Add my company
Life Healthcare Communications

Life is a creative communications agency offering multi-channel solutions for the healthcare industry. We use a storytelling approach to turn...

Latest intelligence

Healing the Healers
Because if we do not heal the healers, who is going to heal us?...
The (inevitable) digital transformation of Medical Affairs
It’s not a question of ‘if,’ it’s a question of ‘when.’...
Oncology eBook: Reducing the care gap in cancer prevention, diagnosis, and treatment
Despite significant innovation in the oncology landscape, there is a growing care gap preventing patients accessing and benefiting from innovations in cancer treatment. In this new publication, our oncology experts...

Quick links